China SXT Pharmaceuticals, Inc. is a pharmaceutical company specializing in the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), including advanced, fine, and regular varieties under the historic 'Su Xuangtang' brand with nearly 280 years of heritage. Based in Taizhou, Jiangsu Province, China, the company blends ancient TCM traditions with modern production techniques, adhering to Good Manufacturing Practices (GMP) to ensure quality, safety, and efficacy in products like TCM granules tailored for hospitals and pharmacies. Established in 2005, it has pursued innovation through substantial R&D investments, including 13 invention patent applications and leadership from Chief Scientific Officer Dr. Jingzhen Deng, who drives strategies for non-decocting, advanced TCMP using aqueous extraction ratios, fingerprint analysis, and bioactive compound quantization. Key milestones include a 2019 strategic partnership with Zhangtai Group for product expansion, ongoing distribution network growth, and production enhancements to meet rising TCM demand. Operating primarily in China's domestic market via a Variable Interest Entity structure, China SXT Pharmaceuticals occupies a niche in the TCM sector, holding about 3% market share among competitors and capitalizing on increasing interest in alternative medicines. Its focus on rigorous quality control and modernization positions it within the evolving pharmaceutical landscape.